Results 111 to 120 of about 72,847 (303)
Derived cannabinoid product availability among online vape shops
Objectives: To determine the proportion of online vape shops that offer derived cannabinoid products in a large metropolitan area (San Diego, California), measure their compliance with state hemp regulations, and estimate whether these shops receive more
Nora Satybaldiyeva +7 more
doaj +1 more source
Abstract Background and aims Cannabis is the most widely used illicit drug worldwide and is often co‐used with tobacco, the leading cause of preventable death. Although cannabis and tobacco have distinct neurobiological actions, their associations with brain volumes are unclear.
Katherine Sawyer +16 more
wiley +1 more source
Pharmacokinetics of Cannabinoids
Delta‐9‐tetrahydrocannabinol (Δ‐9‐THC) is the main psychoactive ingredient of cannabis (marijuana). The present review focuses on the pharmacokinetics of THC, but also includes known information for cannabinol and cannabidiol, as well as the synthetic marketed cannabinoids, dronabinol (synthetic THC) and nabilone.
openaire +3 more sources
Abstract Aim Our primary aim was to conduct a network meta‐analysis (NMA) for the effectiveness, safety and acceptability of all psychosocial interventions and all pharmacotherapies for cannabis use disorder (CUD). Methods We conducted a NMA of studies identified from two completed systematic reviews examining the effectiveness, safety and ...
Monika Halicka +6 more
wiley +1 more source
Abstract Aims To systematically review the evidence on the psychometric performance and accuracy of screening or diagnostic tools for cannabis use disorder. Method Systematic review and meta‐analysis which included studies conducted in clinical settings, schools, universities, community settings and population‐based surveys in multiple countries and ...
Janni Leung +8 more
wiley +1 more source
Antitumoral effects of cannabis in Notch1‐mutated T‐cell acute lymphoblastic leukemia
Elazar Besser +9 more
doaj +1 more source
Beyond abstinence: Redefining success in cannabis use disorder treatment
Abstract Background Over two decades of pharmacotherapy research has yet to yield a consistently effective medication for cannabis use disorder (CUD), in part because clinical trials have frequently prioritized abstinence as a primary or key endpoint.
Tobias B. Atkin +3 more
wiley +1 more source
Anandamide (arachidonoylethanolamide, AEA) acts as endogenous agonist of both cannabinoidand vanilloid receptors. During the last two decades, its metabolic pathways and biologicalactivity have been extensively investigated and relatively well ...
Maccarrone M +7 more
core +1 more source
Urine testing is used in a variety of contexts to identify cannabis use. Most tests target 11-nor-9-carboxy-Δ⁹-tetrahydrocannabinol (11-COOH-THC), the terminal metabolite of Δ⁹-tetrahydrocannabinol (THC), the principal intoxicant in cannabis.
Danielle McCartney +5 more
doaj +1 more source
Abstract Background and Aims The introduction of prescribed medical cannabis in many parts of the world raises issues regarding how we conceptualise Cannabis Use Disorders (CUD). The Diagnostic Statistical Manual Version 5 (DSM5) provides a framework for ‘Prescription Cannabis Use Disorder’ (Pr‐CUD) when a person is using medical cannabis only‐as ...
Nicholas Lintzeris, Llewellyn Mills
wiley +1 more source

